Details
Stereochemistry | ACHIRAL |
Molecular Formula | C14H21N3O2S |
Molecular Weight | 295.4021 |
Optical Activity | NONE |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
CNS(=O)(=O)Cc1ccc2c(c1)c(CCN(C)C)c[nH]2
InChI
InChIKey=KQKPFRSPSRPDEB-UHFFFAOYSA-N
InChI=1S/C14H21N3O2S/c1-15-20(18,19)10-11-4-5-14-13(8-11)12(9-16-14)6-7-17(2)3/h4-5,8-9,15-16H,6-7,10H2,1-3H3
Molecular Formula | C14H21N3O2S |
Molecular Weight | 295.4021 |
Charge | 0 |
Count |
|
Stereochemistry | ACHIRAL |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Optical Activity | NONE |
Sumatriptan is a serotonin (5-HT1B/1D) receptor agonist indicated for acute treatment of migraine with or without aura in adults. Sumatriptan is structurally similar to serotonin (5-HT), and is a 5-HT receptor (types 5-HT1D and 5-HT1B) agonist. The specific receptor subtypes it activates are present on the cranial arteries and veins. Acting as an agonist at these receptors, sumatriptan reduces the vascular inflammation associated with migraines. The specific receptor subtype it activates is present in the cranial and basilar arteries. Activation of these receptors causes vasoconstriction of those dilated arteries. Sumatriptan is also shown to decrease the activity of the trigeminal nerve, which presumably accounts for sumatriptan's efficacy in treating cluster headaches. The injectable form of the drug has been shown to abort a cluster headache within 30 minutes in 77% of cases. Sumatriptan is effective for ending or relieving the intensity of migraine and cluster headaches. It is most effective taken early after the start of the pain. Injected sumatriptan is more effective than other formulations. Large doses of sumatriptan can cause sulfhemoglobinemia, a rare condition in which the blood changes from red to greenish-black, due to the integration of sulfur into the hemoglobin molecule. Serious cardiac events, including some that have been fatal, have occurred following the use of sumatriptan injection or tablets. Events reported have included coronary artery vasospasm, transient myocardial ischemia, myocardial infarction, ventricular tachycardia, and ventricular fibrillation (V-Fib).
Originator
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: CHEMBL214 Sources: https://www.ncbi.nlm.nih.gov/pubmed/8568822 |
330.0 nM [IC50] | ||
Target ID: CHEMBL1898 Sources: https://www.ncbi.nlm.nih.gov/pubmed/9871581 |
38.3 nM [EC50] | ||
Target ID: CHEMBL1805 Sources: https://www.ncbi.nlm.nih.gov/pubmed/11708905 |
35.0 nM [EC50] | ||
Target ID: CHEMBL1983 Sources: https://www.ncbi.nlm.nih.gov/pubmed/14643336 |
5.3 nM [EC50] |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Primary | IMITREX Approved UseSumatriptan Injection, USP is indicated in adults for (1) the acute treatment of migraine, with or without aura, and (2) the acute treatment of cluster headache. Limitations of Use: Use only if a clear diagnosis of migraine or cluster headache has been established. If a patient has no response to the first migraine or cluster headache attack treated with Sumatriptan Injection, USP, reconsider the diagnosis before Sumatriptan Injection, USP is administered to treat any subsequent attacks. Sumatriptan Injection, USP is not indicated for the prevention of migraine or cluster headache attacks. Sumatriptan Injection, USP is a serotonin (5-HT1B/1D) receptor agonist (triptan) indicated for: Acute treatment of migraine with or without aura in adults (1) Acute treatment of cluster headache in adults (1) Limitations of Use: Use only if a clear diagnosis of migraine or cluster headache has been established (1) Not indicated for the prophylactic therapy of migraine or cluster headache attacks (1) Launch Date8.7255358E11 |
|||
Primary | IMITREX Approved UseSumatriptan Injection, USP is indicated in adults for (1) the acute treatment of migraine, with or without aura, and (2) the acute treatment of cluster headache. Limitations of Use: Use only if a clear diagnosis of migraine or cluster headache has been established. If a patient has no response to the first migraine or cluster headache attack treated with Sumatriptan Injection, USP, reconsider the diagnosis before Sumatriptan Injection, USP is administered to treat any subsequent attacks. Sumatriptan Injection, USP is not indicated for the prevention of migraine or cluster headache attacks. Sumatriptan Injection, USP is a serotonin (5-HT1B/1D) receptor agonist (triptan) indicated for: Acute treatment of migraine with or without aura in adults (1) Acute treatment of cluster headache in adults (1) Limitations of Use: Use only if a clear diagnosis of migraine or cluster headache has been established (1) Not indicated for the prophylactic therapy of migraine or cluster headache attacks (1) Launch Date8.7255358E11 |
|||
Primary | IMITREX Approved UseSumatriptan Injection, USP is indicated in adults for (1) the acute treatment of migraine, with or without aura, and (2) the acute treatment of cluster headache. Limitations of Use: Use only if a clear diagnosis of migraine or cluster headache has been established. If a patient has no response to the first migraine or cluster headache attack treated with Sumatriptan Injection, USP, reconsider the diagnosis before Sumatriptan Injection, USP is administered to treat any subsequent attacks. Sumatriptan Injection, USP is not indicated for the prevention of migraine or cluster headache attacks. Sumatriptan Injection, USP is a serotonin (5-HT1B/1D) receptor agonist (triptan) indicated for: Acute treatment of migraine with or without aura in adults (1) Acute treatment of cluster headache in adults (1) Limitations of Use: Use only if a clear diagnosis of migraine or cluster headache has been established (1) Not indicated for the prophylactic therapy of migraine or cluster headache attacks (1) Launch Date8.7255358E11 |
Cmax
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
42 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/7768259/ |
3 mg single, subcutaneous dose: 3 mg route of administration: Subcutaneous experiment type: SINGLE co-administered: |
SUMATRIPTAN plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
|
77 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/7768259/ |
3 mg single, intravenous dose: 3 mg route of administration: Intravenous experiment type: SINGLE co-administered: |
SUMATRIPTAN plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
|
49 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/7768259/ |
100 mg single, oral dose: 100 mg route of administration: Oral experiment type: SINGLE co-administered: |
SUMATRIPTAN plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
|
90 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/7768259/ |
200 mg single, oral dose: 200 mg route of administration: Oral experiment type: SINGLE co-administered: |
SUMATRIPTAN plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
|
18 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/7768259/ |
25 mg single, oral dose: 25 mg route of administration: Oral experiment type: SINGLE co-administered: |
SUMATRIPTAN plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
|
112 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/7768259/ |
300 mg single, oral dose: 300 mg route of administration: Oral experiment type: SINGLE co-administered: |
SUMATRIPTAN plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
|
144 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/7768259/ |
400 mg single, oral dose: 400 mg route of administration: Oral experiment type: SINGLE co-administered: |
SUMATRIPTAN plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
|
29 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/7768259/ |
50 mg single, oral dose: 50 mg route of administration: Oral experiment type: SINGLE co-administered: |
SUMATRIPTAN plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
|
80 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/7768259/ |
8 mg single, subcutaneous dose: 8 mg route of administration: Subcutaneous experiment type: SINGLE co-administered: |
SUMATRIPTAN plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
|
12 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/7768259/ |
1 mg single, subcutaneous dose: 1 mg route of administration: Subcutaneous experiment type: SINGLE co-administered: |
SUMATRIPTAN plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
|
194 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/7768259/ |
16 mg single, subcutaneous dose: 16 mg route of administration: Subcutaneous experiment type: SINGLE co-administered: |
SUMATRIPTAN plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
AUC
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
41 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/7768259/ |
3 mg single, subcutaneous dose: 3 mg route of administration: Subcutaneous experiment type: SINGLE co-administered: |
SUMATRIPTAN plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
|
43 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/7768259/ |
3 mg single, intravenous dose: 3 mg route of administration: Intravenous experiment type: SINGLE co-administered: |
SUMATRIPTAN plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
|
158 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/7768259/ |
100 mg single, oral dose: 100 mg route of administration: Oral experiment type: SINGLE co-administered: |
SUMATRIPTAN plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
|
380 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/7768259/ |
200 mg single, oral dose: 200 mg route of administration: Oral experiment type: SINGLE co-administered: |
SUMATRIPTAN plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
|
44 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/7768259/ |
25 mg single, oral dose: 25 mg route of administration: Oral experiment type: SINGLE co-administered: |
SUMATRIPTAN plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
|
476 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/7768259/ |
300 mg single, oral dose: 300 mg route of administration: Oral experiment type: SINGLE co-administered: |
SUMATRIPTAN plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
|
590 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/7768259/ |
400 mg single, oral dose: 400 mg route of administration: Oral experiment type: SINGLE co-administered: |
SUMATRIPTAN plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
|
83 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/7768259/ |
50 mg single, oral dose: 50 mg route of administration: Oral experiment type: SINGLE co-administered: |
SUMATRIPTAN plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
|
105 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/7768259/ |
8 mg single, subcutaneous dose: 8 mg route of administration: Subcutaneous experiment type: SINGLE co-administered: |
SUMATRIPTAN plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
|
14 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/7768259/ |
1 mg single, subcutaneous dose: 1 mg route of administration: Subcutaneous experiment type: SINGLE co-administered: |
SUMATRIPTAN plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
|
239 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/7768259/ |
16 mg single, subcutaneous dose: 16 mg route of administration: Subcutaneous experiment type: SINGLE co-administered: |
SUMATRIPTAN plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
T1/2
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
1.6 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/7768259/ |
3 mg single, subcutaneous dose: 3 mg route of administration: Subcutaneous experiment type: SINGLE co-administered: |
SUMATRIPTAN plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
|
1.6 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/7768259/ |
3 mg single, intravenous dose: 3 mg route of administration: Intravenous experiment type: SINGLE co-administered: |
SUMATRIPTAN plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
|
2 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/7768259/ |
100 mg single, oral dose: 100 mg route of administration: Oral experiment type: SINGLE co-administered: |
SUMATRIPTAN plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
|
2.1 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/7768259/ |
200 mg single, oral dose: 200 mg route of administration: Oral experiment type: SINGLE co-administered: |
SUMATRIPTAN plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
|
1.5 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/7768259/ |
25 mg single, oral dose: 25 mg route of administration: Oral experiment type: SINGLE co-administered: |
SUMATRIPTAN plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
|
14.4 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/7768259/ |
300 mg single, oral dose: 300 mg route of administration: Oral experiment type: SINGLE co-administered: |
SUMATRIPTAN plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
|
83 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/7768259/ |
400 mg single, oral dose: 400 mg route of administration: Oral experiment type: SINGLE co-administered: |
SUMATRIPTAN plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
|
1.5 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/7768259/ |
50 mg single, oral dose: 50 mg route of administration: Oral experiment type: SINGLE co-administered: |
SUMATRIPTAN plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
|
2 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/7768259/ |
8 mg single, subcutaneous dose: 8 mg route of administration: Subcutaneous experiment type: SINGLE co-administered: |
SUMATRIPTAN plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
|
2 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/7768259/ |
1 mg single, subcutaneous dose: 1 mg route of administration: Subcutaneous experiment type: SINGLE co-administered: |
SUMATRIPTAN plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
|
2.1 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/7768259/ |
16 mg single, subcutaneous dose: 16 mg route of administration: Subcutaneous experiment type: SINGLE co-administered: |
SUMATRIPTAN plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
Doses
Dose | Population | Adverse events |
---|---|---|
200 mg 1 times / month multiple, oral Dose: 200 mg, 1 times / month Route: oral Route: multiple Dose: 200 mg, 1 times / month Sources: |
unhealthy, 18 - 65 years n = 94 Health Status: unhealthy Condition: acute migraine with aura Age Group: 18 - 65 years Sex: M+F Population Size: 94 Sources: |
|
300 mg single, oral Overdose Dose: 300 mg Route: oral Route: single Dose: 300 mg Co-administed with:: (SUMATRIPTAN) Sources: 12 mg subcutaneous injections |
unhealthy, 35 years n = 1 Health Status: unhealthy Condition: migraine Age Group: 35 years Sex: F Population Size: 1 Sources: |
Disc. AE: Ischemic colitis... AEs leading to discontinuation/dose reduction: Ischemic colitis (1 patient) Sources: |
6 mg 2 times / day multiple, subcutaneous Overdose Dose: 6 mg, 2 times / day Route: subcutaneous Route: multiple Dose: 6 mg, 2 times / day Sources: |
unhealthy, 36 years n = 1 Health Status: unhealthy Condition: episodic cluster headache Age Group: 36 years Sex: M Population Size: 1 Sources: |
|
100 mg single, oral Highest studied dose Dose: 100 mg Route: oral Route: single Dose: 100 mg Sources: |
unhealthy, adult n = 437 Health Status: unhealthy Condition: migraine with or without aura Age Group: adult Sex: unknown Population Size: 437 Sources: |
Other AEs: Abnormal physical sensation, Abnormal physical sensation... Other AEs: Abnormal physical sensation (6%) Sources: Abnormal physical sensation (6%) Abnormal physical sensation (6%) Sensation of pressure (8%) Chest tightness of (2%) Throat tightness (3%) Pain (1%) Pressure (3%) Vertigo (2%) Malaise and fatigue (3%) |
AEs
AE | Significance | Dose | Population |
---|---|---|---|
Ischemic colitis | 1 patient Disc. AE |
300 mg single, oral Overdose Dose: 300 mg Route: oral Route: single Dose: 300 mg Co-administed with:: (SUMATRIPTAN) Sources: 12 mg subcutaneous injections |
unhealthy, 35 years n = 1 Health Status: unhealthy Condition: migraine Age Group: 35 years Sex: F Population Size: 1 Sources: |
Pain | 1% | 100 mg single, oral Highest studied dose Dose: 100 mg Route: oral Route: single Dose: 100 mg Sources: |
unhealthy, adult n = 437 Health Status: unhealthy Condition: migraine with or without aura Age Group: adult Sex: unknown Population Size: 437 Sources: |
Chest tightness of | 2% | 100 mg single, oral Highest studied dose Dose: 100 mg Route: oral Route: single Dose: 100 mg Sources: |
unhealthy, adult n = 437 Health Status: unhealthy Condition: migraine with or without aura Age Group: adult Sex: unknown Population Size: 437 Sources: |
Vertigo | 2% | 100 mg single, oral Highest studied dose Dose: 100 mg Route: oral Route: single Dose: 100 mg Sources: |
unhealthy, adult n = 437 Health Status: unhealthy Condition: migraine with or without aura Age Group: adult Sex: unknown Population Size: 437 Sources: |
Malaise and fatigue | 3% | 100 mg single, oral Highest studied dose Dose: 100 mg Route: oral Route: single Dose: 100 mg Sources: |
unhealthy, adult n = 437 Health Status: unhealthy Condition: migraine with or without aura Age Group: adult Sex: unknown Population Size: 437 Sources: |
Pressure | 3% | 100 mg single, oral Highest studied dose Dose: 100 mg Route: oral Route: single Dose: 100 mg Sources: |
unhealthy, adult n = 437 Health Status: unhealthy Condition: migraine with or without aura Age Group: adult Sex: unknown Population Size: 437 Sources: |
Throat tightness | 3% | 100 mg single, oral Highest studied dose Dose: 100 mg Route: oral Route: single Dose: 100 mg Sources: |
unhealthy, adult n = 437 Health Status: unhealthy Condition: migraine with or without aura Age Group: adult Sex: unknown Population Size: 437 Sources: |
Abnormal physical sensation | 6% | 100 mg single, oral Highest studied dose Dose: 100 mg Route: oral Route: single Dose: 100 mg Sources: |
unhealthy, adult n = 437 Health Status: unhealthy Condition: migraine with or without aura Age Group: adult Sex: unknown Population Size: 437 Sources: |
Abnormal physical sensation | 6% | 100 mg single, oral Highest studied dose Dose: 100 mg Route: oral Route: single Dose: 100 mg Sources: |
unhealthy, adult n = 437 Health Status: unhealthy Condition: migraine with or without aura Age Group: adult Sex: unknown Population Size: 437 Sources: |
Abnormal physical sensation | 6% | 100 mg single, oral Highest studied dose Dose: 100 mg Route: oral Route: single Dose: 100 mg Sources: |
unhealthy, adult n = 437 Health Status: unhealthy Condition: migraine with or without aura Age Group: adult Sex: unknown Population Size: 437 Sources: |
Sensation of pressure | 8% | 100 mg single, oral Highest studied dose Dose: 100 mg Route: oral Route: single Dose: 100 mg Sources: |
unhealthy, adult n = 437 Health Status: unhealthy Condition: migraine with or without aura Age Group: adult Sex: unknown Population Size: 437 Sources: |
Overview
CYP3A4 | CYP2C9 | CYP2D6 | hERG |
---|---|---|---|
Drug as perpetrator
Target | Modality | Activity | Metabolite | Clinical evidence |
---|---|---|---|---|
weak | ||||
yes [IC50 6.7 uM] |
Drug as victim
Target | Modality | Activity | Metabolite | Clinical evidence |
---|---|---|---|---|
no | ||||
no | weak (co-administration study) Comment: coadministered with clarithromycin: mean sumatriptan AUC(infinity) and Cmax values after administration of combination treatment were 9% and 14% higher, respectively Sources: https://pubmed.ncbi.nlm.nih.gov/12017403/ |
|||
yes |
PubMed
Title | Date | PubMed |
---|---|---|
Sumatriptan treatment for migraine in a health maintenance organization: economic, humanistic, and clinical outcomes. | 1999 Jan |
|
Fatal cardiac arrhythmia after oral sumatriptan. | 1999 Jul-Aug |
|
Sumatriptan and ergotamine overuse and drug-induced headache: a clinicoepidemiologic study. | 1999 Jul-Aug |
|
An unusual case of renal vein thrombosis in a man taking sumatriptan. | 1999 Jun |
|
Postpartum cerebral angiopathy associated with the administration of sumatriptan and dihydroergotamine--a case report. | 1999 May |
|
Prospective large-scale study of the tolerability of subcutaneous sumatriptan injection for acute treatment of migraine. | 1999 May |
|
Open-labeled long-term study of the efficacy, safety, and tolerability of subcutaneous sumatriptan in acute migraine treatment. | 1999 Sep |
|
Identification of an amino acid residue important for binding of methiothepin and sumatriptan to the human 5-HT(1B) receptor. | 1999 Sep 10 |
|
2000 Wolfe Award. Sumatriptan for the range of headaches in migraine sufferers: results of the Spectrum Study. | 2000 Nov-Dec |
|
New abortive agents for the treatment of migraine. | 2001 |
|
A clinical trial on a plate? The potential of 384-well format solid phase extraction for high-throughput bioanalysis using liquid chromatography/tandem mass spectrometry. | 2001 |
|
Comparative study of a combination of isometheptene mucate, dichloralphenazone with acetaminophen and sumatriptan succinate in the treatment of migraine. | 2001 Apr |
|
Sumatriptan nasal spray and cognitive function during migraine: results of an open-label study. | 2001 Apr |
|
Cluster headache: review of the literature. | 2001 Apr |
|
[Migraine: selection of therapeutic agents to be applied during its attack]. | 2001 Apr 10 |
|
A comparison of visual analog scale and categorical ratings of headache pain in a randomized controlled clinical trial with migraine patients. | 2001 Aug |
|
A systematic review of the use of triptans in acute migraine. | 2001 Feb |
|
Treatment and management of cluster headache. | 2001 Feb |
|
Cortical spreading depression produces increased cGMP levels in cortex and brain stem that is inhibited by tonabersat (SB-220453) but not sumatriptan. | 2001 Feb 9 |
|
Effect of rizatriptan in the spectrum of headache. | 2001 Jun |
|
Sumatriptan can alleviate headaches due to carotid artery dissection. | 2001 Jun |
|
[Anti-migraine drug sumatriptan succinate, a 5-HT1B/1D-receptor agonist]. | 2001 Jun |
|
Colocalization of CGRP with 5-HT1B/1D receptors and substance P in trigeminal ganglion neurons in rats. | 2001 Jun |
|
Recent development in paediatric headache. | 2001 Jun |
|
Headache and female hormones: what you need to know. | 2001 Jun |
|
Relaxation induced by serotonin and sumatriptan in isolated guinea pig gallbladder strips. | 2001 Mar |
|
Gastric motor effects of triptans: open questions and future perspectives. | 2001 Mar |
|
Complicated migraine and migraine variants. | 2001 Mar |
|
Status migrainosus in children and adolescents. | 2001 Mar |
|
Sumatriptin vs dihydroergotamine: patient preference. | 2001 Mar |
|
Zolmitriptan versus sumatriptan comparison trial. | 2001 Mar |
|
Naratriptan as short-term prophylaxis of menstrually associated migraine: a randomized, double-blind, placebo-controlled study. | 2001 Mar |
|
4991W93 inhibits release of calcitonin gene-related peptide in the cat but only at doses with 5HT(1B/1D) receptor agonist activity? | 2001 Mar |
|
Cardiovascular effects of SL65.0472, a 5-HT receptor antagonist. | 2001 Mar 2 |
|
Serotonin-induced hypercontraction through 5-hydroxytryptamine 1B receptors in atherosclerotic rabbit coronary arteries. | 2001 Mar 6 |
|
Effect of MAO-A inhibition on the pharmacokinetics of almotriptan, an antimigraine agent in humans. | 2001 May |
|
An in vivo rat model to study calcitonin gene related peptide release following activation of the trigeminal vascular system. | 2001 May |
Sample Use Guides
Migraine Headache. Oral: 25 mg, 50 mg, or 100 mg PO (taken with fluids); Not to exceed 100 mg/dose; additional doses q2hr PRN. Subcutaneous Injection: 6 mg (0.5 mL) SC with autoinjector; may repeat in ≥1 hr; Not to exceed 12 mg SC q24hr
Cluster Headache. Subcutaneous Injection: 6 mg (0.5 mL) SC with autoinjector; may repeat in ≥1 hour; Not to exceed 12 mg SC q24hr
Route of Administration:
Other
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/26659468
The uptake of sumatriptan and other triptans via OCT1 and OCT3 was characterized using HEK293 cells stably transfected to overexpress wild-type OCT1 or OCT3. For measuring the uptake in human hepatocytes, was used cryopreserved human hepatocytes (Gibco Life Technologies, Darmstadt, Germany) obtained from a single donor with two fully active OCT1 alleles. Triptan uptake in OCT1 and OCT3-overexpressing HEK293 cells was measured by incubating the cells with varying concentrations of the substrates in 12-well plates for two minutes at pH 7.4 and 378C. The reaction was stopped with ice-cold buffer, the cells were lysed with 80% acetonitrile, and the intracellularly accumulated triptans were quantified by liquid chromatography coupled to tandem massspectrometry.
Substance Class |
Chemical
Created
by
admin
on
Edited
Fri Jun 25 20:55:15 UTC 2021
by
admin
on
Fri Jun 25 20:55:15 UTC 2021
|
Record UNII |
8R78F6L9VO
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Brand Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
WHO-VATC |
QN02CC01
Created by
admin on Fri Jun 25 20:55:15 UTC 2021 , Edited by admin on Fri Jun 25 20:55:15 UTC 2021
|
||
|
NCI_THESAURUS |
C47794
Created by
admin on Fri Jun 25 20:55:15 UTC 2021 , Edited by admin on Fri Jun 25 20:55:15 UTC 2021
|
||
|
NDF-RT |
N0000175763
Created by
admin on Fri Jun 25 20:55:15 UTC 2021 , Edited by admin on Fri Jun 25 20:55:15 UTC 2021
|
||
|
LIVERTOX |
916
Created by
admin on Fri Jun 25 20:55:15 UTC 2021 , Edited by admin on Fri Jun 25 20:55:15 UTC 2021
|
||
|
NDF-RT |
N0000175764
Created by
admin on Fri Jun 25 20:55:15 UTC 2021 , Edited by admin on Fri Jun 25 20:55:15 UTC 2021
|
||
|
NDF-RT |
N0000175765
Created by
admin on Fri Jun 25 20:55:15 UTC 2021 , Edited by admin on Fri Jun 25 20:55:15 UTC 2021
|
||
|
WHO-ATC |
N02CC01
Created by
admin on Fri Jun 25 20:55:15 UTC 2021 , Edited by admin on Fri Jun 25 20:55:15 UTC 2021
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
M10396
Created by
admin on Fri Jun 25 20:55:15 UTC 2021 , Edited by admin on Fri Jun 25 20:55:15 UTC 2021
|
PRIMARY | Merck Index | ||
|
2543
Created by
admin on Fri Jun 25 20:55:15 UTC 2021 , Edited by admin on Fri Jun 25 20:55:15 UTC 2021
|
PRIMARY | |||
|
D018170
Created by
admin on Fri Jun 25 20:55:15 UTC 2021 , Edited by admin on Fri Jun 25 20:55:15 UTC 2021
|
PRIMARY | |||
|
C1240
Created by
admin on Fri Jun 25 20:55:15 UTC 2021 , Edited by admin on Fri Jun 25 20:55:15 UTC 2021
|
PRIMARY | |||
|
SUMATRIPTAN
Created by
admin on Fri Jun 25 20:55:15 UTC 2021 , Edited by admin on Fri Jun 25 20:55:15 UTC 2021
|
PRIMARY | |||
|
CHEMBL128
Created by
admin on Fri Jun 25 20:55:15 UTC 2021 , Edited by admin on Fri Jun 25 20:55:15 UTC 2021
|
PRIMARY | |||
|
6125
Created by
admin on Fri Jun 25 20:55:15 UTC 2021 , Edited by admin on Fri Jun 25 20:55:15 UTC 2021
|
PRIMARY | |||
|
103628-46-2
Created by
admin on Fri Jun 25 20:55:15 UTC 2021 , Edited by admin on Fri Jun 25 20:55:15 UTC 2021
|
PRIMARY | |||
|
8R78F6L9VO
Created by
admin on Fri Jun 25 20:55:15 UTC 2021 , Edited by admin on Fri Jun 25 20:55:15 UTC 2021
|
PRIMARY | |||
|
SUB10770MIG
Created by
admin on Fri Jun 25 20:55:15 UTC 2021 , Edited by admin on Fri Jun 25 20:55:15 UTC 2021
|
PRIMARY | |||
|
1642154
Created by
admin on Fri Jun 25 20:55:15 UTC 2021 , Edited by admin on Fri Jun 25 20:55:15 UTC 2021
|
PRIMARY | USP-RS | ||
|
54
Created by
admin on Fri Jun 25 20:55:15 UTC 2021 , Edited by admin on Fri Jun 25 20:55:15 UTC 2021
|
PRIMARY | |||
|
103628-46-2
Created by
admin on Fri Jun 25 20:55:15 UTC 2021 , Edited by admin on Fri Jun 25 20:55:15 UTC 2021
|
PRIMARY | |||
|
37418
Created by
admin on Fri Jun 25 20:55:15 UTC 2021 , Edited by admin on Fri Jun 25 20:55:15 UTC 2021
|
PRIMARY | RxNorm | ||
|
5358
Created by
admin on Fri Jun 25 20:55:15 UTC 2021 , Edited by admin on Fri Jun 25 20:55:15 UTC 2021
|
PRIMARY | |||
|
Sumatriptan
Created by
admin on Fri Jun 25 20:55:15 UTC 2021 , Edited by admin on Fri Jun 25 20:55:15 UTC 2021
|
PRIMARY | |||
|
7742
Created by
admin on Fri Jun 25 20:55:15 UTC 2021 , Edited by admin on Fri Jun 25 20:55:15 UTC 2021
|
PRIMARY | |||
|
DB00669
Created by
admin on Fri Jun 25 20:55:15 UTC 2021 , Edited by admin on Fri Jun 25 20:55:15 UTC 2021
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
TARGET -> AGONIST | |||
|
TARGET -> AGONIST | |||
|
TARGET -> AGONIST | |||
|
SALT/SOLVATE -> PARENT | |||
|
BASIS OF STRENGTH->SUBSTANCE |
ASSAY (HPLC)
USP
|
||
|
BINDER->LIGAND |
BINDING
|
Related Record | Type | Details | ||
---|---|---|---|---|
|
METABOLITE -> PARENT |
URINE
|
Related Record | Type | Details | ||
---|---|---|---|---|
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
|
||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
|
||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
|
||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
|
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |
Name | Property Type | Amount | Referenced Substance | Defining | Parameters | References |
---|---|---|---|---|---|---|
Biological Half-life | PHARMACOKINETIC |
|
|
|||